Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

Rhea-AI Summary

DURHAM, N.C., April 14, 2022 – Heat Biologics (NYSE American: HTBX) will host an investor and media livestream event on April 19, 2022, at 10:30 AM ET to discuss recent developments. The company focuses on first-in-class therapies to modulate the immune system, leveraging its gp96 platform for various product candidates. Notable developments include the completion of enrollment in a Phase 2 trial for HS-110 and ongoing Phase 1 trials for PTX-35 and HS-130.

Positive

• Completion of enrollment in Phase 2 trial for HS-110.
• Ongoing Phase 1 trials for PTX-35 and HS-130.

Negative

• None.

DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31

About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

For more information, please visit: www.heatbio.com, and also follow us on Twitter.

Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com

FAQ

What is the date and time of Heat Biologics' investor event?

Heat Biologics' investor event is scheduled for April 19, 2022, at 10:30 AM ET.

What topics will be discussed during the livestream event hosted by Heat Biologics?

The event will cover the latest developments regarding the company's therapies and programs.

What is the focus of Heat Biologics as a biopharmaceutical company?

Heat Biologics focuses on developing therapies and vaccines to modulate the immune system.

Which trials have Heat Biologics completed or are currently conducting?

Heat Biologics has completed enrollment in a Phase 2 trial for HS-110 and is conducting Phase 1 trials for PTX-35 and HS-130.

What is the stock symbol for Heat Biologics?

The stock symbol for Heat Biologics is HTBX.